Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

JCO Early Release, published online ahead of print Mar 12 2012
Journal of Clinical Oncology, 10.1200/JCO.2011.39.6671

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hollevoet, K.
Right arrow Articles by van Meerbeeck, J. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hollevoet, K.
Right arrow Articles by van Meerbeeck, J. P.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Delicious   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Review Articles

Submitted September 26, 2011; accepted December 13, 2011.

Serum Mesothelin for Diagnosing Malignant Pleural Mesothelioma: An Individual Patient Data Meta-Analysis

Kevin Hollevoet, Johannes B. Reitsma, Jenette Creaney, Bogdan D. Grigoriu, Bruce W. Robinson, Arnaud Scherpereel, Alfonso Cristaudo, Harvey I. Pass, Kristiaan Nackaerts, José A. Rodríguez Portal, Joachim Schneider, Thomas Muley, Francesca Di Serio, Paul Baas, Marco Tomasetti, Alex J. Rai, Jan P. van Meerbeeck

Kevin Hollevoet and Jan P. van Meerbeeck, Ghent University Hospital, Ghent; Kristiaan Nackaerts, University Hospital Gasthuisberg, Leuven, Belgium; Johannes B. Reitsma, University Medical Center Utrecht, Utrecht; Paul Baas, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Jenette Creaney and Bruce W. Robinson, University of Western Australia, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia; Bogdan D. Grigoriu, University of Medicine, Iasi, Romania; Arnaud Scherpereel, University Hospital (Centre Hospitalier Régional et Universitaire) of Lille II, Lille, France; Alfonso Cristaudo, University of Pisa, Pisa; Francesca Di Serio, University Hospital, Bari; Marco Tomasetti, Polytechnic University of Marche, Ancona, Italy; José A. Rodríguez Portal, Virgen del Rocío University Hospital, Seville, Spain; Joachim Schneider, Justus-Liebig Universität, Giessen; Thomas Muley, Thoraxklinik am Universitätsklinikum Heidelberg, Heidelberg, Germany; Kevin Hollevoet, National Cancer Institute, National Institutes of Health, Bethesda, MD; Harvey I. Pass, New York University, Langone Medical Center and Cancer Center; and Alex J. Rai, Columbia University Medical Center, New York, NY.

Corresponding author: Kevin Hollevoet, PhD, Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 37 Convent Dr, Room 5110, Bethesda, MD 20892-4264; e-mail: kevin.hollevoet{at}nih.gov.

Purpose Mesothelin is currently considered the best available serum biomarker of malignant pleural mesothelioma. To examine the diagnostic accuracy and use of serum mesothelin in early diagnosis, we performed an individual patient data (IPD) meta-analysis.

Methods The literature search identified 16 diagnostic studies of serum mesothelin, measured with the Mesomark enzyme-linked immunosorbent assay. IPD of 4,491 individuals were collected, including several control groups and 1,026 patients with malignant pleural mesothelioma. Mesothelin levels were standardized for between-study differences and age, after which the diagnostic accuracy and the factors affecting it were examined with receiver operating characteristic (ROC) regression analysis.

Results At a common diagnostic threshold of 2.00 nmol/L, the sensitivities and specificities of mesothelin in the different studies ranged widely from 19% to 68% and 88% to 100%, respectively. This heterogeneity can be explained by differences in study population, because type of control group, mesothelioma stage, and histologic subtype significantly affected the diagnostic accuracy. The use of mesothelin in early diagnosis was evaluated by differentiating 217 patients with stage I or II epithelioid and biphasic mesothelioma from 1,612 symptomatic or high-risk controls. The resulting area under the ROC curve was 0.77 (95% CI, 0.73 to 0.81). At 95% specificity, mesothelin displayed a sensitivity of 32% (95% CI, 26% to 40%).

Conclusion In patients suspected of having mesothelioma, a positive blood test for mesothelin at a high-specificity threshold is a strong incentive to urge further diagnostic steps. However, the poor sensitivity of mesothelin clearly limits its added value to early diagnosis and emphasizes the need for further biomarker research.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
Eur J Cardiothorac SurgHome page
I. Opitz, R. Bueno, E. Lim, H. Pass, U. Pastorino, M. Boeri, G. Rocco, and on behalf of the ESTS Biology Club
Biomolecular and clinical practice in malignant pleural mesothelioma and lung cancer: what thoracic surgeons should know
Eur J Cardiothorac Surg, October 1, 2014; 46(4): 602 - 606.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
K. Lamote, K. Nackaerts, and J. P. van Meerbeeck
Strengths, Weaknesses, and Opportunities of Diagnostic Breathomics in Pleural Mesothelioma--A Hypothesis
Cancer Epidemiol. Biomarkers Prev., June 1, 2014; 23(6): 898 - 908.
[Abstract] [Full Text] [PDF]


Home page
BMJ OpenHome page
A. Cui, X.-G. Jin, K. Zhai, Z.-H. Tong, and H.-Z. Shi
Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis
BMJ Open, February 23, 2014; 4(2): e004145 - e004145.
[Abstract] [Full Text] [PDF]


Home page
Anticancer ResHome page
M. CORRADI, M. GOLDONI, R. ALINOVI, M. TISEO, L. AMPOLLINI, S. BONINI, P. CARBOGNANI, A. CASALINI, and A. MUTTI
YKL-40 and Mesothelin in the Blood of Patients with Malignant Mesothelioma, Lung Cancer and Asbestosis
Anticancer Res, December 1, 2013; 33(12): 5517 - 5524.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
D. W. Henderson, G. Reid, S. C. Kao, N. van Zandwijk, and S. Klebe
Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers
J. Clin. Pathol., October 1, 2013; 66(10): 847 - 853.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
I. Pantazopoulos, P. Boura, T. Xanthos, and K. Syrigos
Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma
Eur. Respir. J., March 1, 2013; 41(3): 706 - 715.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
R. Kratzke
Detection of Mesothioloma Remains a Conundrum
J Natl Cancer Inst, February 20, 2013; 105(4): 254 - 255.
[Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2012 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online